GlassScriptPhysician profile
Carol A Long
NPI 1982652228
$728.71
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $141 · 2021: $475.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $138.56 | 2021 | |
| Pfizer INC. | $70.99 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.73 | 2020-2021 | |
| Adlon Therapeutics L.P. | $54.72 | 2020-2021 | |
| Glaxosmithkline, LLC. | $49.56 | 2019-2021 | |
| Tris Pharma INC | $47.24 | 2020-2021 | |
| Kaleo, INC. | $44.56 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $41.71 | 2019-2021 | |
| Cranial Technologies, INC | $41.38 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $36.36 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $31.33 | 2021 | |
| Sanofi Pasteur INC. | $23.73 | 2019-2021 | |
| Corium, LLC | $21.39 | 2021 | |
| Aytu Biopharma, INC. | $18.87 | 2019 | |
| Phadia US INC. | $15.67 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $14.38 | 2021 | |
| Quidel Corporation | $9.53 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.